Figures & data
Figure 1 Trough levels of testosterone after repeated injections of testosterone enanthate and testosterone undecanoate in 40 hypogonadal men (mean age 41, range: 18–74 years).
Figure 2 Sexual parameters in 40 hypogonadal men (mean age 41, range: 18–74 years) under treatment with testosterone enanthate or testosterone undecanoate.
Figure 3 Effect of testosterone undecanoate (intervals of 12-weeks) on prostate-specific antigen (PSA) in 40 hypogonadal men (mean age 41, range: 18–74 years).
Figure 4 Disappearance of venous leakage evidenced by cavernosography in a hypogonadal man with erectile dysfunction at baseline (left) and after 3 months’ administration of testosterone undecanoate (right).
Figure 5 Another subject showing absence of venous leakage evidenced by cavernosography in a hypogonadal man with erectile dysfunction at baseline (left) and after 4.5 months’ administration of testosterone undecanoate (right) with better penile composition and opacification.
Figure 6 Improvement in scores on the international index of erectile function (IIEF) in 71 of 122 patients receiving treatment with long-acting testosterone undecanoate.
